Foraviset is a clinical-stage women's health company developing Raviset®, a first-in-class non-hormonal therapy for endometriosis. By targeting the iNOS/nitric oxide pathway, Raviset is designed to address upstream inflammatory and pain mechanisms that drive endometriosis and related uterine disorders. The company is advancing toward Phase II clinical validation while building a broader platform for non-hormonal treatment of uterine pain and bleeding conditions.